This Startup Wants To Catch Cancer Before It Spreads

Episode Summary

Executive Summary: Billion to One built a high-precision blood-based DNA testing platform that first transformed prenatal genetic screening and is now expanding into cancer detection. By adding synthetic DNA controls before amplification, the company reduces noise in ultra-dilute samples, enabling accurate detection of rare variants. The founders used a stepwise commercialization strategy to reach scale, profitability, and a path toward early cancer screening.

Main Topics: Core technology: detecting rare DNA in blood (Priority: 5/5): The company’s platform identifies tiny amounts of fetal or tumor DNA circulating in blood, solving a needle-in-a-haystack problem by using synthetic DNA templates to measure and subtract amplification noise. Prenatal genetic testing as the initial product (Priority: 5/5): Billion to One began with noninvasive prenatal testing for conditions like sickle cell disease, cystic fibrosis, and thalassemias, replacing more invasive approaches for many patients. Commercialization and rapid scaling (Priority: 5/5): The founders moved from idea to live test in about two years, overcame early fundraising and lab constraints, and later scaled to hundreds of thousands of tests annually and a public-company valuation. Operational lab automation and AI (Priority: 4/5): The transcript highlights the lab workflow, including accessioning, centrifugation, plasma separation, barcode tracking, and AI/computer vision to speed sample handling and preserve identity at scale. Expansion into oncology and liquid biopsy (Priority: 5/5): The same cell-free DNA technology now supports cancer testing, including an early commercial liquid biopsy product and a near-term ultra-sensitive MRD test for stage 1-2 patients. Long-term vision: early cancer screening (Priority: 5/5): The founders describe a stepwise plan from prenatal testing to late-stage cancer to early-stage cancer detection, aiming eventually to detect cancer before it reaches stage 1. Team structure and culture (Priority: 3/5): Billion to One emphasizes interdisciplinary scientists, small end-to-end product teams, and a high-challenge culture framed as 'pressure is a privilege.'

Key Arguments: Rare fetal and tumor DNA can be detected from blood if amplification noise is controlled. Synthetic DNA spike-ins let the company quantify and remove PCR-induced errors, turning a biology problem into a mathematical one. An interdisciplinary approach combining chemistry, data science, and bioinformatics was essential to solving the problem. Starting with prenatal testing was strategically easier and more capital-efficient than beginning with oncology or early cancer screening. The company’s platform is broadly applicable because fetal DNA and tumor DNA are both cell-free DNA in blood. Automation, AI, and computer vision are necessary to process samples at high volume while preserving accuracy. Commercial traction in prenatal testing created the resources and credibility needed to expand into cancer diagnostics. A stepwise product roadmap is the only practical way to reach early cancer screening without raising enormous capital upfront. The company believes its MRD test could detect microscopic residual disease after surgery and eventually support population-level cancer screening. The team culture favors small, autonomous, interdisciplinary groups that can iterate quickly and own products end-to-end.

Data Points: Babies screened in America this year: 1 in 11 - Opening framing of how widely the prenatal genetic test is being adopted Human genome size: 3 billion base pairs - Used to explain the scale of the detection problem Genetic difference often being sought: 1 base pair - Illustrates how small the signal is relative to the genome Annual test volume: More than 600,000 tests per year - Current operating scale of Billion to One Market share: Close to 20% - Overall market share in the prenatal testing market Company valuation at IPO/public listing: Over $4 billion - Late last year the company went public at this valuation Time to first commercial test: About 2 years - From PhD-student idea to live commercial test Initial lab space: Half a lab bench in a shared facility - Early startup constraints Initial fundraising: $300,000 - First post-fellowship capital raised Fundraising duration: 6 months - Time it took to raise the first $300,000 Early fundraising increments: $10,000 at a time - Illustrates how constrained the company was early on Initial launch traction: 1 physician user - Two months after launch, usage was still extremely low Sales hiring push: 5 additional sales reps in 3 weeks - Emergency response to weak early adoption Patient outreach conversion: About 1 in 5 kids back - Marketing-led patient outreach helped generate physician adoption Lab processing time: 5 to 7 days - Sample workflow duration through the lab Accessioning time: 60 seconds per file - Human handling time before AI/computer vision redesign Future facility capacity: Close to 2 million tests per year - Projected throughput using the current facility Potential population coverage: Around 1 in 3 babies - Estimated prenatal testing coverage at that capacity Cancer product launch: 2023 - Early commercial liquid biopsy product launch year MRD launch timeline: Less than a year away - Near-term plan for ultra-sensitive minimal residual disease testing Residual disease prevalence after curative surgery: About 20% - Stage 1-2 cancer patients may still have microscopic remaining disease

Pivotal Quotes: "We have realized that DNA that is coming from the fetus and the tumor is both very dilute and rare." — Ozan: Explaining the central technical challenge behind the platform "What we have done is to add a synthetic DNA into the patient sample that we get before any amplification happens." — Ozan: Describing the key innovation that enables error correction "Once we are there, I think technically we would have sold the, you know, holy grail of cancer detection." — Ozan: Referring to the long-term goal of early cancer screening

Implications: The company shows how a capital-efficient, stepwise platform can move from prenatal diagnostics to cancer detection. If successful, it could reshape screening, MRD monitoring, and early cancer detection across medicine.